Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: corbuspharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/28/2025 | Outperform | William Blair | |
| 12/2/2024 | Overweight | Piper Sandler | |
| 7/30/2024 | $85.00 | Outperform | Wedbush |
| 7/22/2024 | $80.00 | Buy | H.C. Wainwright |
| 6/26/2024 | $85.00 | Buy | B. Riley Securities |
| 6/3/2024 | $60.00 → $80.00 | Outperform | Oppenheimer |
| 5/13/2024 | $77.00 | Outperform | RBC Capital Mkts |
| 3/6/2024 | $4.00 → $46.00 | Hold → Buy | Jefferies |
SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
3 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
3 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled for completion Q3 2025 and Phase 1b dose-range finding scheduled for completion H2 2026 NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the single ascending dose / multiple ascending dose (SAD/MAD) portion of the Phase 1 trial of CRB-913 for the treatment of obesity. The study is being conducted in the
CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study Fast Track Designation granted by FDA for CRB-701 to treat metastatic cervical cancerCRB 913 SAD/MAD obesity study expected to start in March 2025$149m of cash & investments as of December 31,2024 and cash runway expected through Q3 2027 NORWOOD, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2024. "During the fourth quarter and into 2025, we made si
NORWOOD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in the following upcoming investor conferences. B. Riley Securities Precision Oncology & Radiopharma Investor ConferenceFormat: Panel and one-on-one investor meetingsPanel Title: Unlocking the Full Potential of Nectin-4 Targeting TherapiesDate: February 28, 2025Time: 8:00 a.m. ET TD Cowen 45th Annual Health Care ConferenceFormat: Presentation and one-on-one investor meetingsDate: March 4, 2025Time: 1:50 p.m. ETWebcast: Click here Wedbush Securities Cardiometabolic Co
Study mirrored 4 highest doses used in China dose escalation study presented at ASCO 2024 Safety, tolerability and PK comparable to China dataset with no DLTs observed in either study Low levels of peripheral neuropathy and skin toxicity observed in both studies Clinical responses seen in urothelial (mUC) and cervical cancer participants in both studies First time targeting of head and neck squamous cell carcinoma (HNSCC) with CRB-701 yields multiple responses Dose optimization is underway with dosing at 2.7 mg/kg and 3.6 mg/kg Q3W NORWOOD, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), announced that data from it
NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe ("Western study") of CRB-701 (SYS6002) has been released. The corresponding up-to-date data will be presented as a poster during the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The data from 31 patients referred to in the abstract dates to September 2024; the upcoming poster presentation will include data on 38 patients as of December 2024. ASCO GU will be held in San Francisco, CA February 1
NORWOOD, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the Guggenheim SMID Cap Biotech Conference, to be held February 5-6, 2025 in New York, NY Dr. Cohen will participate in analyst led fireside discussion and will attend one-on-one investor meetings. Guggenheim Securities SMID Cap Biotech ConferenceFormat: Fireside Chat and one-on-one investor meetingsPresentation Date: February 5, 2025Presentation Time: 2:30 PMWebcast: Click here About Corbus Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity comp
NORWOOD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced data from its first-in-human dose escalation clinical study conducted in the United States and the United Kingdom ("Western study") of CRB-701 (SYS6002) will be presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), to be held in San Francisco, CA February 13–15, 2025. The poster is titled Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tutors (Perez, et al) and will be
NORWOOD, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the 43rd Annual J.P. Morgan Healthcare Conference, to be held January 13-16, 2025 in San Francisco, CA. Dr. Cohen will be presenting and attending investor meetings. 43rd Annual J.P. Morgan Healthcare ConferenceFormat: Presentation and one-on-one investor meetingsPresentation Date: January 16, 2025Presentation Time 11:15 a.m. PST The J.P. Morgan Healthcare Conference is invitation only. Those interested in attending should contact their J.P. Morgan representat
NORWOOD, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, today announced the dosing of the first patient in the Phase 1 portion of the clinical study of CRB-601 for the treatment of patients with advanced solid tumors (NCT06603844). CRB-601 is a monoclonal antibody targeting latent TGFβ activation-by blocking the integrin αVβ8. Pre-clinical data has demonstrated that CRB-601 overcomes tumor immune exclusion and enhances the activity of immune checkpoint inhibitors in vivo. "CRB-601 offers an intriguing upstream approach to modulating TGFβ signaling and t
NORWOOD, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer. CRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting Nectin-4 that contains a site-specific, cleavable linker and a precise drug antibody ratio of 2 using MMAE as the payload. The FDA's Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to
William Blair initiated coverage of Corbus Pharma with a rating of Outperform
Piper Sandler initiated coverage of Corbus Pharma with a rating of Overweight
Wedbush initiated coverage of Corbus Pharma with a rating of Outperform and set a new price target of $85.00
H.C. Wainwright resumed coverage of Corbus Pharma with a rating of Buy and set a new price target of $80.00
B. Riley Securities initiated coverage of Corbus Pharma with a rating of Buy and set a new price target of $85.00
Oppenheimer reiterated coverage of Corbus Pharma with a rating of Outperform and set a new price target of $80.00 from $60.00 previously
RBC Capital Mkts initiated coverage of Corbus Pharma with a rating of Outperform and set a new price target of $77.00
Jefferies upgraded Corbus Pharma from Hold to Buy and set a new price target of $46.00 from $4.00 previously
Oppenheimer resumed coverage of Corbus Pharmaceuticals with a rating of Hold
DEFA14A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
DEF 14A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
10-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
SCHEDULE 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
144 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. "With this track record of success in both the pharma industry and on Wall Street, Winston has earned a well-deserved reputation for his leadership and financial acumen," said Alan F. Holmer, Chairman of the Corbus Board of Directors. "We are delighted to welcome someone of Winston's stature and expertise to our Board and we look forward to his insights and guidance." "Winston brings an e
NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company's Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company's investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partnership with CSPC, and CRB-601, a TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company's h
NORWOOD, Mass., March 6, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the appointment of Yong Ben, M.D., MBA, to the Company's Board of Directors. "Dr. Ben is a distinguished oncology researcher and pharma industry executive, with multiple drug approvals to his credit, and his appointment is a welcome addition to our Board," said Alan Holmer, Chairman of the Board of Directors of Corbus. "Our recent license agreement for CRB-701 has helped cement our position as a precision o
NORWOOD, Mass., Sept. 26, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an immunology company, today announced the appointment of Anne Altmeyer, PhD, MBA, MPH to its board of directors. "Anne is a dynamic leader with a proven track record of advancing R&D programs and creating corporate value through successful business development transactions," said Alan Holmer, Chairman of the Board of Directors of Corbus. "Her corporate development expertise and oncology R&D experience will be invaluable to Corbus as we advance and
NEW YORK and LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LBT4) systems are implicated, today announced the appointment of Rachelle Jacques as President and Chief Executive Officer of Akari Therapeutics. Ms. Jacques will also join the company's Board of Directors. Her appointment begins at the end of March 2022. Outgoing Chief Executive Officer, Clive Richardson, will continue to serve the Company, supporting Rachelle to accelerate business development and ensuring a smooth transition."
NORWOOD, Mass., Dec. 7, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company") today announced the appointment of Rachael Brake, Ph.D., as Chief Scientific Officer, furthering the Company's mission of connecting innovation to purpose. Dr. Brake will build upon Corbus' commitment to immuno-oncology and joins the Company following the recent acquisition of monoclonal antibodies that inhibit TGFβ activation. Dr. Brake most recently served at Takeda Pharmaceuticals where she held multiple leadership roles across the R&D continuum, inc
LEXINGTON, Mass. and AMSTERDAM, Oct. 21, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Rachelle Jacques to its Board of Directors. Ms. Jacques, who will serve on the Board's Audit Committee, has more than 25 years of industry experience in strategic, cross-functional executive roles spanning finance, business operations, manufacturing, and commercial. She has led successful launches of several rare disease therapies including the recent approval of a Regenerative Medicine Advanced Therapy (RMAT)-designated product, one of only three since the p